Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 153

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 153
---
 stock and warrants for an additional 468,750 shares of Common Stock.                  |

| f. | On November 14, 2023, following the execution of an agreement with LipoVation Ltd, the Company issued                                       
 5,699,218 Common stock and 2,849,609 warrants to purchase Common stock of the Company to certain investors for a consideration of $5,668.75 
 (out of which $100 were received in the first quarter of 2024) which were previously received as an advance payment on account of shares.   
 See Note 5a. Of the warrants issued, warrants for 1,437,500 shares have a per share exercise price of $0.80 and warrants for 1,412,109      
 shares have a per share exercise price of $2.40. The warrants are exercisable through December 31, 2026.                                    |

| g. | On December 21, 2023, the Company received $112.5 from the private placement of units of the Company’s                                   
 securities where each unit (a “Unit” and collectively the “Units”) is comprised of (i) two (2) share of the Company’s                    
 Common Stock par value $0.001 per share and (ii) a warrant to purchase an additional share of the company's Common Stock, exercisable    
 for a three-year period at a per share exercise price of $2.40, all at a per Unit purchase price of $3.20. As a result, the investor was 
 issued 70,313 shares of Common stock and warrants for an additional 35,156 shares of Common Stock, exercisable through 31 December 2026. |

<div align='center'>F-45</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6 – STOCKHOLDERS’ EQUITY (Cont.)

| h. | On September 30, 2021, the Company granted options under its Global Share Incentive Plan (2021) to directors,                           
 employees and service providers to purchase an aggregate of 4,800,000 shares of Common Stock exercisable through the eighth anniversary 
 (8th) of the issuance at a per share exercise price of $0.40. Of the options granted, 3,300,000 were to senior officers and directors.  |

During the year ended December